Copyright
©The Author(s) 2023.
World J Clin Cases. Jul 26, 2023; 11(21): 5083-5096
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5083
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5083
Figure 2 Flow chart of the study procedure.
The patients enrolled in the present study received three infusions on days 7, 14, and 21. They participated in four visits, occurring on days 0, 28, 84, and 180. ECG: Electrocardiogram; Hu-MSCs: Human umbilical cord-mesenchymal stem cells.
- Citation: Lian XF, Lu DH, Liu HL, Liu YJ, Yang Y, Lin Y, Xie F, Huang CH, Wu HM, Long AM, Hui CJ, Shi Y, Chen Y, Gao YF, Zhang F. Safety evaluation of human umbilical cord-mesenchymal stem cells in type 2 diabetes mellitus treatment: A phase 2 clinical trial. World J Clin Cases 2023; 11(21): 5083-5096
- URL: https://www.wjgnet.com/2307-8960/full/v11/i21/5083.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i21.5083